Literature DB >> 25625932

Vaccines versus immunotherapy: overview of approaches in deciding between options.

Angus G Dalgleish1.   

Abstract

This review compares the optimal use of vaccines vs. other forms of immunotherapy, which includes cytokines, such as IL-2, monoclonal antibodies, such as the 'checkpoint inhibitors', against CTLA-4 and PD-1. The review includes both prophylactic and therapeutic vaccines using a variety of technologies. It is already established that vaccines can be enhanced by other immunotherapies, such as cytokines (IL-2) and there is scope for combining both of these with the 'checkpoint' antibodies. Moreover, both can be enhanced with other modalities, such as radiotherapy, ablative therapy and both high and low dose chemotherapies.

Entities:  

Keywords:  BCG, Bacillus Colmette Guerin; CpG, cytosine-phosphate-guanosine; GM-CSF, Granulocyte-macrophage colony-stimulating factor; HBV, Human hepatitis virus; HPV, Human papilloma virus; IL-2, Interleukin-2; PFS, progression free survival; PSA, Prostate-specific antigen; TGFβ, Tumour growth factor beta; TLR, Toll-like receptor; antibodies; checkpoint inhibitors; cytokines; immune modulators; immunotherapy; therapeutic vaccines

Mesh:

Substances:

Year:  2014        PMID: 25625932      PMCID: PMC4517456          DOI: 10.4161/21645515.2014.980707

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  60 in total

1.  Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity.

Authors:  Keith Dredge; J Blake Marriott; Stephen M Todryk; George W Muller; Roger Chen; David I Stirling; Angus G Dalgleish
Journal:  J Immunol       Date:  2002-05-15       Impact factor: 5.422

2.  Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine.

Authors:  Eddy C Hsueh; Richard Essner; Leland J Foshag; David W Ollila; Guy Gammon; Steven J O'Day; Peter D Boasberg; Stacey L Stern; Xing Ye; Donald L Morton
Journal:  J Clin Oncol       Date:  2002-12-01       Impact factor: 44.544

3.  Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model.

Authors:  Ian F Hermans; Tsung Wen Chong; Michael J Palmowski; Adrian L Harris; Vincenzo Cerundolo
Journal:  Cancer Res       Date:  2003-12-01       Impact factor: 12.701

4.  A randomized phase II trial of SRL172 (Mycobacterium vaccae) +/- low-dose interleukin-2 in the treatment of metastatic malignant melanoma.

Authors:  S Nicholson; K Guile; J John; I A Clarke; J Diffley; P Donnellan; A Michael; P Szlosarek; A G Dalgleish
Journal:  Melanoma Res       Date:  2003-08       Impact factor: 3.599

5.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).

Authors:  E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij
Journal:  Eur J Cancer       Date:  2009-01       Impact factor: 9.162

6.  Long-term survival and outcome of patients originally given Mycobacterium vaccae for metastatic malignant melanoma.

Authors:  Ferdinando C M Cananzi; Satvinder Mudan; Mary Dunne; Nneka Belonwu; Angus G Dalgleish
Journal:  Hum Vaccin Immunother       Date:  2013-07-09       Impact factor: 3.452

Review 7.  Determinant spreading and tumor responses after peptide-based cancer immunotherapy.

Authors:  Antoni Ribas; John M Timmerman; Lisa H Butterfield; James S Economou
Journal:  Trends Immunol       Date:  2003-02       Impact factor: 16.687

8.  Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes.

Authors:  Donald L Morton; Eddy C Hsueh; Richard Essner; Leland J Foshag; Steven J O'Day; Anton Bilchik; Rishab K Gupta; Dave S B Hoon; Mepur Ravindranath; J Anne Nizze; Guy Gammon; Leslie A Wanek; He-Jing Wang; Robert M Elashoff
Journal:  Ann Surg       Date:  2002-10       Impact factor: 12.969

9.  Immunotherapeutical potential of Mycobacterium vaccae on M. tuberculosis infection in mice.

Authors:  Li Jun Xu; Yan Yan Wang; Xiao Dong Zheng; Xiang Dong Gui; Li Feng Tao; Hai Ming Wei
Journal:  Cell Mol Immunol       Date:  2009-02       Impact factor: 11.530

Review 10.  Chronic immune activation and inflammation as the cause of malignancy.

Authors:  K J O'Byrne; A G Dalgleish
Journal:  Br J Cancer       Date:  2001-08-17       Impact factor: 7.640

View more
  6 in total

Review 1.  hrHPV E5 oncoprotein: immune evasion and related immunotherapies.

Authors:  Antonio Carlos de Freitas; Talita Helena Araújo de Oliveira; Marconi Rego Barros; Aldo Venuti
Journal:  J Exp Clin Cancer Res       Date:  2017-05-25

Review 2.  Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer-Current Treatment Options and Future Perspectives.

Authors:  Evangelos Koustas; Eleni-Myrto Trifylli; Panagiotis Sarantis; Nikolaos Papadopoulos; Eleni Karapedi; Georgios Aloizos; Christos Damaskos; Nikolaos Garmpis; Anna Garmpi; Kostas A Papavassiliou; Michalis V Karamouzis; Athanasios G Papavassiliou
Journal:  Int J Mol Sci       Date:  2022-06-15       Impact factor: 6.208

3.  An efficient and scalable synthesis of potent TLR2 agonistic PAM2CSK4.

Authors:  Arshpreet Kaur; Madhuri T Patil; Surinder K Mehta; Deepak B Salunke
Journal:  RSC Adv       Date:  2018-03-05       Impact factor: 4.036

Review 4.  Clinical translation of immunomodulatory therapeutics.

Authors:  Amanda Nash; Samira Aghlara-Fotovat; Andrea Hernandez; Christopher Scull; Omid Veiseh
Journal:  Adv Drug Deliv Rev       Date:  2021-07-27       Impact factor: 17.873

5.  Anti-PD-1 increases the clonality and activity of tumor infiltrating antigen specific T cells induced by a potent immune therapy consisting of vaccine and metronomic cyclophosphamide.

Authors:  Genevieve M Weir; Olga Hrytsenko; Tara Quinton; Neil L Berinstein; Marianne M Stanford; Marc Mansour
Journal:  J Immunother Cancer       Date:  2016-10-18       Impact factor: 13.751

6.  Complete Clinical Remission of Stage IV Triple-Negative Breast Cancer Lung Metastasis Administering Low-Dose Immune Checkpoint Blockade in Combination With Hyperthermia and Interleukin-2.

Authors:  Ralf Kleef; Ralph Moss; A Marcell Szasz; Arthur Bohdjalian; Hans Bojar; Tibor Bakacs
Journal:  Integr Cancer Ther       Date:  2018-09-07       Impact factor: 3.279

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.